**Core Concept**
The question is testing the association between a specific oncogene and a particular type of thyroid cancer, namely Medullary carcinoma of the thyroid. This is a classic example of a molecular pathology question, where the underlying principle is the genetic basis of cancer.

**Why the Correct Answer is Right**
Medullary thyroid carcinoma (MTC) is a type of thyroid cancer that originates from the parafollicular cells, also known as C cells. The expression of the RET proto-oncogene is commonly associated with MTC. The RET gene encodes a receptor tyrosine kinase that plays a crucial role in the development and function of the C cells. Mutations in the RET gene can lead to the activation of the receptor, resulting in uncontrolled cell proliferation and tumorigenesis.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because the expression of the BRAF V600E mutation is associated with Papillary thyroid carcinoma, not Medullary carcinoma.

**Option B:** This option is incorrect because the expression of the RAS gene mutations is associated with a variety of cancers, including colorectal, pancreatic, and thyroid cancers, but not specifically with Medullary carcinoma.

**Option C:** This option is incorrect because the expression of the TP53 gene mutations is associated with a variety of cancers, including breast, lung, and colorectal cancers, but not specifically with Medullary carcinoma.

**Clinical Pearl / High-Yield Fact**
The RET proto-oncogene is a well-established genetic marker for Medullary thyroid carcinoma, and its expression is commonly used as a diagnostic marker for this condition.

**Correct Answer: D**. RET proto-oncogene.